Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,866 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 45,838 · Balance 343,866 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 384,058 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 40,192 · Balance 384,058 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 314,058 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 70,000 · Balance 314,058 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 404,608 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 404,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418315 · ownership.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 70,000 | $38.61 | $2,702,700.00 |
DisclosureSEC source: 0001193125-26-418315 · ownership.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,058 F4 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 40,192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418315 · ownership.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,058 F3 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 45,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418315 · ownership.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,866 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 564 | $36.69 | $20,693.16 |
DisclosureSEC source: 0001628280-26-063078 · wk-form4_1790111510.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,269 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 627 | $35.38 | $22,183.26 |
DisclosureSEC source: 0001628280-26-061388 · wk-form4_1789073432.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,833 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| July 07, 2026 Filed Jul 13, 2026 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 516 | $27.79 | $14,339.64 |
DisclosureSEC source: 0001628280-26-048053 · wk-form4_1783976605.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,460 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 564 | $26.04 | $14,686.56 |
DisclosureSEC source: 0001628280-26-044694 · wk-form4_1782161398.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,976 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 21:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 627 | $26.10 | $16,364.70 |
DisclosureSEC source: 0001628280-26-042284 · wk-form4_1781125276.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,540 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 515 | $19.27 | $9,924.05 |
DisclosureSEC source: 0001628280-26-024767 · wk-form4_1775856566.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,167 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 2,255 | $19.12 | $43,115.60 |
DisclosureSEC source: 0001628280-26-020574 · wk-form4_1774300102.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,682 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 529 | $20.74 | $10,971.46 |
DisclosureSEC source: 0001628280-26-015340 · wk-form4_1772748620.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 392,937 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 15,585 | $22.65 | $353,000.25 |
DisclosureSEC source: 0001628280-26-012473 · wk-form4_1772146532.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,466 F3 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 39,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012473 · wk-form4_1772146532.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,051 F2 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 20,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012473 · wk-form4_1772146532.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,446 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 405 | $25.59 | $10,363.95 |
DisclosureSEC source: 0001628280-26-001383 · wk-form4_1767909839.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 349,350 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 09, 2025 Filed Dec 17, 2025 22:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 631 | $25.13 | $15,857.03 |
DisclosureSEC source: 0001628280-25-057724 · wk-form4_1766010377.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 349,755 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 526 | $26.74 | $14,065.24 |
DisclosureSEC source: 0001628280-25-054278 · wk-form4_1764369306.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,386 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 21:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 509 | $27.36 | $13,926.24 |
DisclosureSEC source: 0001628280-25-045017 · wk-form4_1760477434.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,912 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 630 | $26.83 | $16,902.90 |
DisclosureSEC source: 0001556355-25-000003 · wk-form4_1757970134.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,421 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 531 | $25.44 | $13,508.64 |
DisclosureSEC source: 0001628280-25-041304 · wk-form4_1756415249.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,051 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 536 | $22.27 | $11,936.72 |
DisclosureSEC source: 0001628280-25-034682 · wk-form4_1752098045.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,582 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 637 | $23.70 | $15,096.90 |
DisclosureSEC source: 0001628280-25-031102 · wk-form4_1749763462.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,118 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 45,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-028700 · wk-form4_1748642526.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,755 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the fourth anniversary of the measurement date of 05-29-2025. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 521 | $22.46 | $11,701.66 |
DisclosureSEC source: 0001628280-25-028700 · wk-form4_1748642526.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,486 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 569 | $20.11 | $11,442.59 |
DisclosureSEC source: 0001628280-25-017588 · wk-form4_1744408167.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,007 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,589 | $22.66 | $239,946.74 |
DisclosureSEC source: 0001628280-25-016633 · wk-form4_1743716875.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,576 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 36,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014184 · wk-form4_1742512090.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,165 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 22,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014184 · wk-form4_1742512090.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,520 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,597 | $25.00 | $39,925.00 |
DisclosureSEC source: 0001628280-25-012679 · wk-form4_1741901168.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,601 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 425 | $25.46 | $10,820.50 |
DisclosureSEC source: 0001628280-25-010565 · wk-form4_1741212812.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,198 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:47 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 92 | $26.54 | $2,441.68 |
DisclosureSEC source: 0001628280-25-005844 · wk-form4_1739573226.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,623 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 00:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 404 | $27.02 | $10,916.08 |
DisclosureSEC source: 0001628280-25-000986 · wk-form4_1736381459.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,715 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 22:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 13,196 | $27.16 | $358,403.36 |
DisclosureSEC source: 0001628280-24-052104 · wk-form4_1734646743.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,119 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 6-14-2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.62 to $27.48, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 22:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,604 | $27.33 | $207,817.32 |
DisclosureSEC source: 0001628280-24-052104 · wk-form4_1734646743.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,315 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 6-14-2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.88 to $28.33, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 22:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 523 | $27.20 | $14,225.60 |
DisclosureSEC source: 0001628280-24-049479 · wk-form4_1732919397.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,919 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 22:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 17,604 | $20.05 | $352,960.20 |
DisclosureSEC source: 0001628280-24-048542 · wk-form4_1732055527.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,442 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-14-2024. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001628280-24-048542 · wk-form4_1732055527.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 15,000 | $21.17 | $317,550.00 |
DisclosureSEC source: 0001628280-24-048542 · wk-form4_1732055527.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,046 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-14-2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.79 to $21.68, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $21.16 | $211,600.00 |
DisclosureSEC source: 0001628280-24-048542 · wk-form4_1732055527.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,046 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-14-2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.82 to $21.68, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:32 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001628280-24-048542 · wk-form4_1732055527.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 327,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 23:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 123 | $26.34 | $3,239.82 |
DisclosureSEC source: 0001628280-24-047993 · wk-form4_1731627466.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,046 F1 · shares: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 547 | $23.15 | $12,663.05 |
DisclosureSEC source: 0001628280-24-044812 · wk-form4_1730502090.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,169 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $23.17 | $231,700.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · nonDerivative · entry 4 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,716 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-14-2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.90 to $23.53, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · nonDerivative · entry 3 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 327,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · derivative · entry 5 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $23.28 | $232,800.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · nonDerivative · entry 2 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,716 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-14-2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.01 to $23.49, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $2.06 | $20,600.00 |
DisclosureSEC source: 0001628280-24-043067 · wk-form4_1729203937.xml · nonDerivative · entry 1 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 327,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 21:36 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001628280-24-041062 · wk-form4_1726868175.xml · derivative · entry 6 Mathew Aby J. · CIK 0001556355 · EVP & Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2025-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.